Navigation Links
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
Date:3/5/2008

YEAR ENDED DECEMBER 31, 2007

Consolidated revenues for the year ended December 31, 2007 were $42.1 million compared to $38.8 million for the same period in 2006. The increase in revenues for 2007 is mainly related to increased sales of Cetrotide(R) and Impavido(R), partly compensated by lower license fees revenues from the Company's partners.

Consolidated R&D costs were $39.2 million for the year ended December 31, 2007 compared to $27.4 million for the same period in 2006. The increase in R&D expenses of $11.8 million in 2007 is mainly related to the advancement of the Company's lead product cetrorelix in Phase 3 for BPH; as well as to further advancement of targeted, earlier-stage development programs including AEZS-108, a cytotoxic conjugate and AEZS-112, a tubulin inhibitor.

Consolidated loss from operations increased to $34.8 million for the year ended December 31, 2007 compared to $23.8 million for the same period in 2006. The increase in loss from operations in 2007 is attributable to a combination of lower license revenues, increase in non-recurring G&A corporate expenses and additional R&D expenses mainly related to the advancement of the Company's Phase 3 program with cetrorelix in BPH. This increase in loss from operations in 2007 was partly offset by increased sales and royalties, as well as lower D&A expenses.

Consolidated net loss was $32.3 million or $0.61 per basic and diluted share for the year ended December 31, 2007 compared to consolidated net earnings of $33.4 million or $0.64 per basic share and $0.62 per diluted share for the same period in 2006. The increased net loss in 2007 is related to a higher loss from operations of nearly $10 million, lower income tax recovery of nearly $27 million related to the recognition of future income tax assets, mainly attributable to the sale of Atrium shares in 2006, and the special distribution of AEterna Zentaris' remaining interest in January 2007, as well as lower net earnings
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
2. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
3. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
4. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
7. AEterna Zentaris Announces Outcome of Managements Strategic Review
8. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
9. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
10. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
11. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jacobs Automotive, a group of car dealerships headquartered in ... Blood Center and offering free oil change coupons for participation ... Jan. 18 at the Bill Jacobs Cadillac and Chevrolet location ... http://photos.prnewswire.com/prnh/20140115/MN46637 )  The Bill Jacobs Auto annual ...
(Date:1/15/2014)... IL (PRWEB) January 15, 2014 Look ... find hard-working items for the lab, from fluid handling ... Guaranteed-in-Stock (GIS)—ready to ship when you order. , ... Peristaltic Pumps , from the L/S® model for precise ...
(Date:1/15/2014)... ­ RedBrick Health , a fast-growing leader in ... that EmblemHealth , the New York ... providing the RedBrick Compass health assessment, combined with the ... its members. EmblemHealth is among the first health plans ...
(Date:1/15/2014)... 2014 More than 5 million Americans ... in 3 seniors will die with Alzheimer’s or another ... figures have shocked many Americans into looking for ways ... these tragic age-related cognitive disorders. Jonathan Weisman, president of ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2
... , , , ... , 2Q09 Corporate Highlights: , ... of Qutenza for treatment of peripheral neuropathic pain in non-diabetic adults, either alone ... Entered exclusive agreement with Astellas Pharma Europe Ltd. (Astellas) for commercialization of ...
... , , Honorees for ... be recognized at Sept. 30 gala ceremony , ... Galien USA will recognize innovative biopharmaceutical drugs and medical technologies that ... at a gala event on September 30. Candidates for the 2009 ...
... ALBANY, Ore., Aug. 6 Synthetech, Inc. (OTC Bulletin Board: ... 2010, which ended June 30, 2009. Revenue for the quarter ... million in the first quarter of fiscal 2009. Operating income ... of $314,000 for the same period last year. Net income ...
Cached Biology Technology:NeurogesX Reports Second Quarter 2009 Results 2NeurogesX Reports Second Quarter 2009 Results 3NeurogesX Reports Second Quarter 2009 Results 4NeurogesX Reports Second Quarter 2009 Results 5NeurogesX Reports Second Quarter 2009 Results 6NeurogesX Reports Second Quarter 2009 Results 7NeurogesX Reports Second Quarter 2009 Results 8NeurogesX Reports Second Quarter 2009 Results 9NeurogesX Reports Second Quarter 2009 Results 10NeurogesX Reports Second Quarter 2009 Results 11NeurogesX Reports Second Quarter 2009 Results 12Prix Galien USA Announces 2009 Final Candidates 2Synthetech Reports First Quarter Fiscal 2010 Results 2Synthetech Reports First Quarter Fiscal 2010 Results 3Synthetech Reports First Quarter Fiscal 2010 Results 4Synthetech Reports First Quarter Fiscal 2010 Results 5Synthetech Reports First Quarter Fiscal 2010 Results 6
(Date:4/18/2014)... that sprout as soon as they,re planted may be good ... more careful. In the wild, a plant whose seeds sprouted ... disaster. More than just an insurance policy against late frosts ... has long-term advantages too: Plants whose seeds put off ... species, finds in a team of researchers working at the ...
(Date:4/18/2014)... of researchers led by a University of California, Riverside ... $7.5 million Department of Defense grant to uncover fundamental ... for the predictable design of light-weight, tough and strong ... from plants and animals, including the mantis shrimp, toucan ... have constructed over millions of years and coming up ...
(Date:4/17/2014)... A drug under clinical trials to treat tuberculosis ... drugs that act against various bacteria, fungal infections and ... University of Illinois chemists and collaborators. , Led by ... determined the different ways the drug SQ109 attacks the ... target other pathogens from yeast to malaria and ...
Breaking Biology News(10 mins):Plants with dormant seeds give rise to more species 2Mantis shrimp, toucan and trilobite, oh my 2Mantis shrimp, toucan and trilobite, oh my 3Multitarget TB drug could treat other diseases, evade resistance 2
... will develop and coordinate a strategic federal research ... breast cancer. The 19-member Interagency Breast Cancer and ... the National Institute of Environmental Health Sciences (NIEHS), ... to review all breast cancer research efforts conducted ...
... for Age Research have successfully used human induced pluripotent ... Disease (PD). The research, which validates a scalable ... be used to manufacture the type of neurons needed ... the use of iPSC,s in various biomedical applications. Results ...
... package developed by a professor at the Virginia Bioinformatics ... understand the workings of biochemical networks now features an ... benefits to its users. In development for over ... collaboration between VBI Professor Pedro Mendes, research groups at ...
Cached Biology News:New breast cancer committee to establish federal research agenda 2New breast cancer committee to establish federal research agenda 3Scientists successfully use human induced pluripotent stem cells to treat Parkinson's in rodents 2Systems biology software package developed at VBI is now open source for all users 2
... Our Accumix standard is a new ... mode electrospray ionization mass spectrometry. Accumix ... broad mass range coverage for both tuning ... LCQ- and LTQ-MS) and Fourier transform mass ...
Goat Anti-Horse IgG(T) Antibody, Unconjugated...
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
Biology Products: